Stocktoria
Organon & Co. OGN
NYSE · XNYS · stock · Pharmaceutical Preparations · website · IPO 2021-05-14
Organon & Co. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 53.3% | 58.0% | 59.8% | 62.8% | — |
| Net margin | 3.0% | 13.5% | 16.3% | 14.9% | 21.4% |
| FCF margin | 8.7% | 11.9% | 8.7% | 10.7% | 31.2% |
| Return on assets | 1.5% | 6.6% | 8.5% | 8.4% | 12.6% |
| Return on equity | 24.9% | 183.1% | -1461.4% | -102.8% | -89.6% |
| Debt / equity | 11.49× | 18.81× | -125.14× | -9.99× | -6.06× |
| Current ratio | 1.82 | 1.60 | 1.54 | 1.56 | 1.45 |
| Revenue growth | -2.9% | 2.2% | 1.4% | -2.1% | -3.5% |
Source: SEC EDGAR filings · CIK 0001821825 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.